Aridis Pharmaceuticals, Inc. (ARDS)
After hours:
| Previous Close | 0.6713 |
| Open | 0.6900 |
| Bid | 0.6700 x 1300 |
| Ask | 0.6690 x 2900 |
| Day's Range | 0.6600 - 0.6900 |
| 52 Week Range | 0.5700 - 2.9400 |
| Volume | |
| Avg. Volume | 895,611 |
| Market Cap | 17.883M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2630 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Zacks
Here's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Aridis Pharmaceuticals (ARDS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- GlobeNewswire
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). AR-301-002, the first of two planned Phase 3 studies, enrolled
- GlobeNewswire
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infectiv
